Plains GP Holdings (PAGP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 May, 2026Executive summary
Board recommends voting FOR Proposal 3, the advisory vote to approve 2025 named executive officer compensation, at the 2026 annual meetings.
ISS recommended voting against Proposal 3, while Glass Lewis recommended voting for it.
Board disagrees with ISS's concerns and provides detailed responses to each point.
Voting matters and shareholder proposals
Proposal 3 seeks shareholder approval of 2025 named executive officer compensation on an advisory basis.
Board urges shareholders and unitholders to vote FOR Proposal 3 at the 2026 annual meetings.
Board of directors and corporate governance
Board approved extension of CEO's 2018 Promotional Grant to retain the CEO for up to five additional years and support succession planning.
Extension intended to ensure stability and continued execution of key strategic initiatives.
Latest events from Plains GP Holdings
- Robust EBITDA growth, high yield, and tax-efficient structure drive strong returns for investors.PAGP
Investor presentation - Q2 2026 net income soared to $1.83B on NGL sale gains, with EBITDA and leverage improving.PAGP
Q2 2026 - Cynthia B. Taylor joins as an independent director, enhancing board expertise and ESG oversight.PAGP
Proxy filing - Sector-leading yield, efficient growth, and robust cash flow drive multi-year distribution growth.PAGP
Investor presentation - 2026 EBITDA guidance raised to $2.88B as NGL sale proceeds target debt reduction.PAGP
Q1 2026 - Proxy covers director elections, auditor ratification, executive pay, and major 2025 strategic actions.PAGP
Proxy filing - Key votes include director elections, auditor ratification, and executive pay approval.PAGP
Proxy filing - 2025 saw $2.83B EBITDA, higher distributions, and a strategic NGL exit with strong 2026 outlook.PAGP
Q4 2025 - Q3 Adjusted EBITDA hit $659M, leverage improved, and bolt-on deals and legal settlements drove growth.PAGP
Q3 2024